

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

## Institutional Biosafety Committee Meeting minutes

### Meeting Attendance:

- Members in attendance:
  - Elena Demireva
  - Jonathan Hardy
  - Dave Morgan
  - Jamie Willard-Smith
  - Sarah Roosa
  - Andras Komaromy
  - Carrie Anglewicz
  - Jan Patterson Samson
  - Guo-Qing Song
- Members not in attendance:
  - Raj Kulkarni
  - Michael Bachmann
  - Carolina de Aguiar Ferreira
  - Simon Petersen-Jones
- Others in attendance:
  - Chris Colvin
  - Alessandra Hunt
  - Luis Ochoa Carrera

### Call to order:

Elena Demireva

### Roll call:

Chris Colvin

### Discussion of the agenda:

- Approved as written.

### Discussion of minutes:

- Approved as written.

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

## Registration review:

### Study Info

**Safety0001214:** [REDACTED]

[REDACTED] - Epigenetic regulation of development and abiotic stress responses in *Zea mays* (maize).

**Training: Complete for all members listed**

**NIH III E-2-a, RG-1, BSL-1**

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
  - 3b: Remove Taq Polymerase, T4 DNA Ligase and BsaI from inserts. Add RUBY, GFP and guide RNA's cassettes, include biological activity and source.
  - 5a. Leave E.coli and Agro only as hosts
- rDNA Work Description
  - 2: Remove bacteria as they are hosts.
  - 7c: Add Agrobacterium as a delivery system.

### Study Info

**Safety0001240:** [REDACTED]

**Study of gene regulatory networks in plants**

**Training: Complete for all members listed**

**NIH III E-2-a, RG-1, BSL-1**

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
  - The citation for James et al is incomplete, add more information for this reference.
- rDNA usage
  - 3b: Add Cas9 and include biological activity and source.
- Supporting Documents
  - Remove old sharps forms as no use of sharps with human or infectious materials stated.

### Study Info

**Safety0001245:** [REDACTED]

[REDACTED] pH signaling

**Training: Complete for all members listed**

**NIH III D-4-b, RG-1, BSL-1**

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
  - 1: If amplifying plasmids in bacteria, include the bacteria section.
  - 2: State that the zebrafish cells are not being generated in the lab.
  - 2: What genes are being overexpressed. Remove GPR68 details if not used.
- rDNA Usage
  - 3b: Add GPR68 insert if used. Include biological activity and source for all inserts.
  - 4a: Explain how and why vectors are to being used in the research.
  - 4b. Remove prices
  - 4c: Change to Yes, answer the follow-up questions.
  - 5a: If cloning in bacteria or making in-house plasmids change to Yes.
  - 10: Include that you will notify EHS and MSU police in case of loss or theft.
- rDNA Work Description
  - 1: Add links or references or Addgene numbers for vectors thare being procured.
  - 7d: List any potential target genes.

## Study Info

**Safety0001260:** [REDACTED]

**Microbial experimental evolution and genome engineering**

**Training: Complete for all members listed**

**NIH III E, RG-1, BSL-1**

This registration has been approved with edits. The PI has been asked to clarify the following:

- Bacteria
  - 1: Add Serratia symbiotica if using in this study.
  - 3e: Missing information on Flow Core Addendum for A. baylyi (are any inserts oncogenes).
- rDNA Usage
  - 3b: Add source and biological activity for all inserts, including Cas9 and reporters.
  - 6. Tet is repeated twice
- rDNA Work Description
  - 5: Change to Yes for use of phage
  - 7d: Remove “various”, be specific, can state you are doing a screen.

## Study Info

**Safety0001262:** [REDACTED]

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

## **Genetic engineering of insect symbionts**

**Training: Complete for all members listed**

**NIH III E-2-2(5), RG-1, BSL-1**

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Work Description
  - 1: Remove statement “we make many constructs for different experiments”. Answer No if not procuring any vectors but only making in house.
  - 7a: Clarify candidates from screen will be targeted in future experiments.
  - 7d: Remove “various”, be specific, can state you are doing a screen.

## Study Info

**Safety0001265:** [REDACTED]

**DiRita- Campy, Vibrio, Entero (2025)**

**Training: Complete for all members listed**

**NIH III D-2, RG-2, BSL-2**

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
  - 3c: Remove the 2 sentences.
  - 5a: Remove materials that are recipients to host question #2 on rDNA work description page.
- rDNA Work Description
  - 2. Remove bacteria (E. coli). This list needs the recipients from the above host list
- Exposure Assessment
  - 2: Define when it is necessary for surgical masks to be used or refer to SOP, if not related to biosafety this can be removed.

## Study Info

**Safety0001269:** [REDACTED]

**Morgan Alzheimer’s Disease Research Lab 2025**

**Training: Complete for all members listed**

**NIH III D-4-b, RG-2, BSL-2**

This registration has been approved with edits. Dr. David Morgan abstains from the vote. The PI has been asked to clarify the following:

- rDNA Usage
  - 4b: Add plasmids used for AAV production.
- Risk Group
  - 1: Update to RG-1

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

## Study Info

**Safety0001271:** [REDACTED]

**[REDACTED] Lab Projects 2025**

**Training: Complete for all members listed**

**NIH III D-4-b, RG-2, BSL-2**

This registration has been approved with edits. Dr. David Morgan abstains from the vote.

The PI has been asked to clarify the following:

- Cells
  - Update the “other” (HMC3) cells if available in the menu or add information for these cells to question #2.
- rDNA Usage
  - 4b: Add any plasmids (e.g. packaging) used for virus production.
  - 8: For #3 Need to address insertional mutagenesis risks for lentivirus
- rDNA Work Description
  - 4: Change to Yes for VSV pseudotyping.
- Exposure Assessment
  - 1: Include BBP exposure from human cell lines as well.
- Supporting Documents
  - Update task procedure for work with Lentivirus.

## Study Info

**Safety0001272:** [REDACTED]

**[REDACTED]: In vivo imaging and therapy**

**Training: Complete for all members listed**

**NIH III E-3, RG-2, BSL-2**

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
  - 1: Include Bacteria section if making plasmids in house.
  - 1: Include Virus section if using Lentivirus, this is unclear throughout the document as there are references to Lentivirus in some sections.
- Cells
  - 1: Double check that all recipient cell lines have been added to the cell line table, e.g. MOC lines are missing.
  - 1: Review BSL for cells and update all human cell lines to BSL-2.
- rDNA Usage
  - 3b: Missing bioactivity and sources for some insert. Cas9 activity is RNA-guided endonuclease.
  - 8,9: Need to be included if using Lentiviral vectors.
- rDNA Work Description
  - 4, 5, 6: Should be yes if using Lentivirus and making plasmids in house.

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

- Exposure Assessment
  - 1: Include statement on Lentivirus if using.
  - 3: Include aerosol centrifuge lids
  - 3: Update eyewash flush date
- Supporting Documents
  - Review and update documents sharps documents, remove old sharps forms.
  - If sharps are NOT being used with infectious or human materials they can be removed.

## Study Info

**Safety0001273:** [REDACTED]

**2025 Reproductive gene regulation**

**Training: Complete for all members listed**

**NIH III D-4-b, RG-2, BSL-2**

This registration has been approved with edits. The PI has been asked to clarify the following:

- Virus
  - Update “other” to AAV, change to BSL-2 for light chain TnT.
- rDNA Usage
  - 3b: Add species for “in vivo use” list inserts. Define biological activity for inserts.
- rDNA Work Description
  - 3: Yes for TnT
- Exposure Assessment
  - 3. update eye wash flush date

## Study Info

**Safety0001281:** [REDACTED]

**Mechanism of spermatogenesis 2025**

**Training: Complete for all members listed**

**NIH III E-1, RG-1, BSL-2**

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
  - 1: Add Tissue section if collecting tissues from mice.
- Cells
  - #3: Add “other” information for testes.
- rDNA Usage
  - 5a. Leave only E.coli
- rDNA Work Description
  - 2: Remove E. coli as this is a host.

# Institutional Biosafety Committee Meeting

8/4/25

1:30-3:00pm

Zoom Virtual Meeting

---

- Supporting Documents
  - Remove sharps forms if none are used with infectious or human materials.

## New Items:

- No Items

## Previous Submissions:

- Safety0001223 [REDACTED]
- Safety0001206 [REDACTED]
- Safety0001257 [REDACTED]

## Next Meeting:

August 18, 2025 1:30 pm via zoom